Guatemala vs Malaysia: Average cost of drugs for extensively drug-resistant tuberculosis
Guatemala
11,910 constant 2022 US$
in 2024
Malaysia
10,000 constant 2022 US$
in 2024
Guatemala rank
3rd
Malaysia rank
4th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Guatemala
- Malaysia
How they compare
Guatemala currently reports 11,910 constant 2022 US$ against 10,000 constant 2022 US$ in Malaysia, a difference of 1,910 constant 2022 US$.
That makes Guatemala's figure about 1.2 times Malaysia's.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Malaysia ahead.
Guatemala ranks 3rd and Malaysia ranks 4th of 56 countries.
Malaysia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guatemala | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 11,075 constant 2022 US$ | 45,000 constant 2022 US$ | 33,925 constant 2022 US$ | Malaysia |
| 2020s | 5,989 constant 2022 US$ | 22,000 constant 2022 US$ | 16,011 constant 2022 US$ | Malaysia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Guatemala or Malaysia?
- Guatemala, at 11,910 constant 2022 US$ against 10,000 constant 2022 US$ in Malaysia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Guatemala and Malaysia?
- 1,910 constant 2022 US$, with Guatemala ahead.
- How many years of comparable data are there for Guatemala and Malaysia?
- 7 years are reported by both, from 2017 to 2024.
- How do Guatemala and Malaysia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Guatemala ranks 3rd and Malaysia ranks 4th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.